ArticleHematological oncology2025

Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.

Enrica Antonia Martino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.